

Bob Champion Cancer Trust

Unaudited

Trustees' Report and Financial Statements

For the year ended 30 June 2025

Bob Champion Cancer Trust

Contents

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 8
Trustees' responsibilities statement	9
Independent examiner's report	10
Statement of financial activities	11
Balance sheet	12
Statement of cash flows	13
Notes to the financial statements	14 - 28

Bob Champion Cancer Trust

Reference and administrative details of the Charity, its Trustees and advisers For the year ended 30 June 2025

Founder

Professor Sir Michael Peckham MD FRCP FRCR (deceased October 2021)

President

Bob Champion, C.B.E.

Medical Advisor

Professor David Dearnaley

Vice Presidents

Clare Balding, O.B.E.

Willie Carson, O.B.E.

Kristina Cook

David Gower, M.B.E.

Chris Hughes

Jonjo O'Neill

Greg Rusedski, Esq.

Peter Shilton, O.B.E.

Nick Skelton, C.B.E.

Trustees

Michael I Cattermole, Esq. (Chairman)

Susie Burrage, O.B.E.

Alex Embiricos

Timothy Fox, Esq.

Andrew Franklin, Esq.

Catherine McAleavey

Catherine Nash

Luke Ponsonby, Esq.

Bridget Rosser

Carolyn Jane Zetter Wells

Trust Officer

Mrs. Lucienne Wilkinson

Charity registered number

1024664

Principal Office

7 Square Rigger Row

Plantation Wharf

London

SW11 3TZ

Accountants

UHY Hacker Young

Chartered Accountants

Thames House

Roman Square

Sittingbourne

Kent ME10 4BJ

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2025

The Trustees present their report and the accounts for the year ended 30 June 2025.

The financial statements comply with the charity's Trust Deed, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) (Charities SORP (FRS 102)).

Administrative Details

A Declaration of Trust formed the Charity on 29 June 1993 registered number 1024664. The purpose of the establishment of this charitable trust was to take over and enlarge the work of the Bob Champion Cancer Trust that was set up by a Declaration of Trust dated 20 January 1983.

The number of Trustees shall not be less than three or more than ten. The power of appointing new Trustees is vested in the Trustees and may be exercised by a resolution in writing signed by all of the current Trustees and the new Trustee. The Trustees meet four times per calendar year in person or online.

Please see page 1 for Trustee details, legal and other administrative detail.

Structure, Governance and Management

The Trust was set up to support research into the causation, nature and treatment of patients with testicular cancer and other forms of malignant disease including those of the prostate.

The Trustees acknowledge their responsibility for ensuring that the major risks to which the Charity is exposed are identified and systems designed to mitigate those risks. During the year the Trustees completed a formal risk management process to assess business risks and risk management strategies.

The Trust has an independent Medical Advisor, Professor David Dearnaley, to advise the board in their selection of grant awards and allow the Charity to operate in open competition with peer review.

Objectives and Activities

The Bob Champion Cancer Trust currently supports cancer research within the Institute of Cancer Research, The Royal Marsden Hospital in Sutton, Surrey and the Bob Champion Research and Education Building, situated in the Norwich Research Park at the University of East Anglia. The focus of this support is on urological cancers, especially those of the prostate.

The Trust opened in collaboration with the Institute of Cancer Research the Bob Champion Research Centre in 2000, which formed part of the first male dedicated cancer research centre, in Europe. This centre is based at The Institute of Cancer Research in Sutton, Surrey.

In February 2015 the Trust, with The University of East Anglia (UEA), opened the Bob Champion Research and Education Building at The Norwich Research Park, this facility is operated by the UEA in partnership with the Norfolk & Norwich Hospital. This centre provides state-of-the-art laboratories for researchers to explore new treatments, not only for prostate cancer research but for diseases from antibiotic resistance to musculo-skeletal and gastrointestinal diseases. This £19 million facility includes a unique bio-bank facility to store DNA and tissue samples plus teaching facilities suitable for training medical practitioners in rooms reflecting the functions of operational hospital bays.

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2025

The Trust is self-supporting and relies totally upon donations from the public that may be in the form of a legacy or donation with the benefit of claiming Gift Aid if applicable. Income is raised from a full fundraising calendar, with major events being held annually or biennially, supported by event committees, active social media platforms and direct promotional mailings and a News Letter. The fundraising events range from themed parties, horse shows and race nights to personal challenges such as sponsored rides, marathons, including the London Marathon and the Shetland Pony Grand National. Hopefully offering something for all our supporters, which also helps to attract new interest to the cause, active involvement from members of the public to support us by organising their own events is also encouraged.

An annual charity raceday at Plumpton Racecourse is held, now in its eighth year, which is an established and extremely popular fundraiser. During the day a Shetland Pony race is held as an extra attraction which helps raise further funds as well as the traditional auctions and raffles. Another very successful event is a carol service - Carols and Champagne - held at Chelsea Old Church in London every other year. A traditional church service is followed by a drinks party in the church hall attached and is very popular with the order of service raising extra funds from advertisers. The Trust is hoping to establish a second raceday which could host a charity race.

The Trust is delighted to be continuing its long-standing involvement with the Shetland Pony Grand National (SPGN), now for the ninth year. The SPGN is a major part of the London International Horse Show held at the ExCel Exhibition Centre, with the SPGN grand finale, a highlight of the four day event. Bob Champion himself is heavily involved during the year, helping the young riders through their heats, and attends, as well as appearing in the show ring every day during the Show. The ten jockeys (aged between 9-14 years) once they qualify to compete via the heats commit to raise a minimum of £1,000 sponsorship in support of the Trust, although, with determined future jockeys, nearly all participants way surpass this goal.

Since 1988 the Trust has produced its own, especially commissioned, double sided Christmas card and since 2021 a second smaller card. The cards not only raise vital funds for research work but spreads awareness of the Trust and it's work and helps keep racing's greatest fairy tale of Bob Champion and Aldaniti's 1981 win alive. The artists are selected each year and kindly donate their work and time in support of the Trust. The larger card offers a more classic choice with the smaller card being more fun. The Trust has found that sales have suffered due to continuing increased postage costs but the cards still represent an important part of the Trusts awareness message.

Bob Champion was awarded a CBE in The Queen's New Year Honours 2021 for his charitable works. He still attends many of the events himself, despite continued health issues, and continues to play an integral part in raising funds, and awareness, not only of the Charity's aims, but also of the disease itself. All events are organised from the office, often with the help of a specific event committee made up from volunteers and keen supporters. The Trust is always open to new fundraising ideas and how to offer help to cancer sufferers, their families and friends.

Public Benefit

The Trustees confirm that they given due consideration to the Charity Commission's published guidance on the Public Benefit requirement under the Charities Act 2011 when reviewing the aims and objectives, and in planning future activities.

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2025

Achievements and performance

Each year 64,000 men in the UK will be diagnosed with prostate cancer and more than 12,000 will die from their disease. At present we do not have good markers to predict who will have prostate cancer that behaves in an aggressive way and causes mortality.

For many cancers the fundamental mechanism of cancer development has been unravelled. Such studies reveal that the disease develops because of alterations or mutations within 'cancer genes'. Although cancer genes responsible for the development of, for example, colon cancer and breast cancer are well characterised, relatively little is known about the fundamental development of prostate cancer.

The Bob Champion Research Trust funded researchers have worked together as part of international consortium, called The Pan Prostate Cancer Group, set up by Professor Colin Cooper at The University of East Anglia (UEA) and Professor Ros Eeles the Institute of Cancer Research (ICR) to analyse genetic data from prostate cancer samples across nine countries.

Application of Artificial Intelligence to results obtained in the UK has helped scientists reveal two distinct forms of prostate cancer called Evotypes, with one being very aggressive prostate cancer. These results could revolutionise how the disease is diagnosed and managed, since it is important that treatment is targeted to aggressive disease.

Crucially, the team aims to develop a genetic test that, when combined with conventional staging and grading, can provide a more precise prognosis for each patient, allowing tailored treatment decisions.

The researchers used AI to study changes in the DNA of prostate cancer samples (using whole genome sequencing) from 159 patients. They identified two distinct cancer groups among these patients using an AI technique called neural networks. These two groups were confirmed by using two other mathematical approaches applied to different aspects of the data. This finding was validated in other independent datasets from Canada and Australia.

The work published in the Journal Cancer Genomics in 2024 was carried out in collaboration with Dr Dan Woodcock at the University of Oxford and Professor David Wedge at the University of Manchester who led the research. The team hope their findings could save thousands of lives in future and revolutionise how prostate cancer is diagnosed and treated. Ultimately, it could provide tailored treatments to each individual patient according to a genetic test which will also be delivered using AI.

Although prostate cancer is responsible for a large proportion of all male cancer deaths, it is more commonly a disease men die with rather than from. This means that unnecessary treatment can often be avoided, sparing men from side-effects such as incontinence and impotence.

These studies are important as until now, it was thought that prostate cancer was just one type of disease. But now, with advancements in artificial intelligence, the researchers have been able to show that there are actually two different subtypes at play.

Hopefully the findings will not only save lives through better diagnosis and tailored treatments in the future, but they may help researchers working in other cancer fields better understand other types of cancer too.

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2025

Professor Ros Eeles, Professor of Oncogenetics at The Institute of Cancer Research, London, and Honorary Consultant in Clinical Oncology and Cancer Genetics at The Royal Marsden NHS Foundation Trust, confirms that this study has utilised the enormous genomic dataset from The Pan Prostate Cancer Group which is a powerhouse of information about prostate cancer from around the world.

The Trust also supports Professor Ros Eeles with a three year grant for the UKGPCS collection of germline DNA and data. The aim of this project is to analyse whole exome sequence from a unique and large collection of prostate cancer cases: 20,000 germline DNA samples from the UKGPCS in order to identify rare variants and their contribution to the risk of developing prostate cancer with specific phenotypes and potentially predict response to various treatments.

The UKGPCS was established in 1992, recruiting men from The Royal Marsden NHS Foundation Trust and Collaborative Centres (NHS Trust hospitals) throughout the UK and Northern Ireland, over 180 of which are from the National Cancer Research Network (NCRN).

The UKGPCS have collected a rich phenotype dataset for most of these samples: date of birth, diagnosis, and death if applicable; mode of detection; TNM Stage; Gleason score; primary treatment; vital status; geographic region based on referring hospital, or treatment hospital if information on the referring hospital was not available; self-reported BMI; self-reported ethnicity; and PSA at diagnosis for all patients, as well as for relatives, if available. The information on risk factors for prostate cancer, demographic characteristics, and clinical data are also collected routinely as part of medical care and clinical follow-up. Over 78% of the cohort has clinical data on treatment and outcomes are being followed up at 2, 5 and 10 years post diagnosis; this collection is still in process.

For sequencing of whole exomes in germline samples a high-throughput automated approach will be used to prepare high-quality genomic DNA for exome capture. The exome will be captured and sequenced on the latest technology in use at the Regeneron Genetics Centre.

The latest study 'Whole Exome Rare Variant Association' focuses on identifying rare genetic variants that may influence the risk and development of any prostate cancer (PrCa), or aggressive disease with poorer prognosis, through association testing. The primary data used in this investigation are Whole Exome Sequencing (WES) data from the UK Genetic Prostate Cancer Study (UKGPCS). An additional objective involves the comparison of germline mutation frequencies in UKGPCS PrCa cases to the UK population using data from UK Biobank (UKBB).

The Trust extended the original three year grant for a further three years for Annie Gao, a Senior Radiotherapy Clinical Trials Co-ordinator and awarded a three year grant to Lily Gilder as Trial Assistant, at the Bob Champion Unit, Royal Marsden Hospital, Sutton

The Unit has supported and lead the PACE trials which looks to use stereotactic body radiotherapy to deliver to the patient the prostate cancer treatment in 5 visits over 1-2 weeks. This pioneering treatment can target the cancer with pinpoint accuracy. This means a reduction in healthy tissue damage and enables men to complete and recover from treatment much faster than ever before. Initial results from the PACE-B trial have been published, showing that there were low rates of side effects after 2 years and suggesting that curative treatment can be given over a much-shortened period. This has positive implications for the patient's experience of cancer treatment and subsequent quality of life.

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2025

Critical to the success of all these studies is the long-term follow-up of men after their initial radiotherapy treatment. Confidence that a patient is truly cured takes 10 years in men with localised prostate cancer as side effects can continue to develop over many years, a full estimation of the risks and benefits of a new treatment requires years of careful data collection.

Annie Gao and her team focus particularly on the long-term follow-up of patients. This enables the ICR to continue to monitor men for signs of cancer recurrence and side effects for long enough to be sure that the innovative radiotherapy treatment being tested is advantageous. The Unit continues to publish results in the highest calibre journals and publications.

Key trials in long term follow-up:

- The **IMRT (Intensity-Modulated Radiotherapy) trial** (495 patients) looked at targeting the prostate cancer more accurately, which in turn allowed for a larger dose of radiotherapy to be given. There were 5 groups of patients, each receiving slightly different doses of radiotherapy. The continued review of this comprehensive dataset enables us to learn more about which patients are likely to be cured with standard treatments and which require further escalation of therapy. Blood and biopsy translational work from this trial also sheds new light on the evolutionary genetics of prostate cancer.
- The **CHHiP trial** (398 patients recruited at RMH out of 3,200 in multi-centre trial) follows patients for up to 15 years after their treatment and is enabling us to know with greater certainty that shorter treatments are better for men with localised prostate cancer. The trial introduced prostate IMRT in the UK. This ongoing data collection has enabled the review of over 2000 prostate cancer samples to further investigate the effects of radiotherapy dose on prostate cancer in the laboratory.
- The **DELINEATE trial** (316 patients), looks at new ways of planning and giving radiotherapy for localised prostate cancer. New types of scanning techniques have allowed us to differentiate between the cancer and normal prostate tissue with greater certainty. The aim is to target the cancerous area with increased accuracy and a higher dose without risking damage to the normal prostate tissue. The Trust has directly impacted this trial by allowing it to extend the patient follow-up period from 5 to 10 years. This data collection is critical as the cure rates have so far been unprecedented with up to 96.7 % of patients being free of any prostate cancer at the 5-year follow-up timepoint. Further follow-up of these patients is necessary to ensure these excellent results are maintained at 10 years.
- The **PACE-C trial** compares stereotactic body radiotherapy (5 visits – SBRT uses precise daily image guidance to give remarkably accurate radiotherapy) with the now conventional IMRT (20 visits – see IMRT trials above). Since the application last year, recruitment to this trial has exceeded expectations and the trial closed early having already met its target of 1182 patients. These men are now in long-term follow-up, assessing side effects, patient quality of life and long-term cancer control.

Publications:-

Distinct druggable biological processes in early-onset prostate cancer

Authors: Stephanie T Schmidt^{1†}, Zsofia Kote-Jarai^{2†}, Adrian Larkeryd^{2†}, Byrum Ozer^{2†}, Questa Karlsson², James Campbell³, Sue Merson², Nicola Dennis⁴, Steven Hazell⁴, Costas Mitsopoulos⁵, Colin Cooper⁶, The ICGC-UK[§], TCGA Consortium[§], Paul Workman⁵, Rosalind A Eeles^{2,4*}, Bissan Al-Lazikani^{1,7*}

Bob Champion Cancer Trust

Trustees' report (continued)
For the year ended 30 June 2025

Esentürk E, Sahli A, Haberland V, Ziuboniewicz A, Wirth C, Bova GS, Bristow RG, Brook MN, Brors B, Butler A, Cancel-Tassin G, Cheng KC, Cooper CS, Corcoran NM, Cussenot O, Eeles RA, Favero F, Gerhäuser C, Gihawi A, Girma EG, Gnanapragasam VJ, Gruber AJ, Hamid A, Hayes VM, He HH, Hovens CM, Imada EL, Jakobsdottir GM, Jung CH, Khani F, Kote-Jarai Z, Lamy P, Leeman G, Loda M, Lutsik P, Marchionni L, Molania R, Papenfuss AT, Pellegrina D, Pope B, Queiroz LR, Rausch T, Reimand J, Robinson B, Schlomm T, Sørensen KD, Uhrig S, Weischenfeldt J, Xu Y, Yamaguchi TN, Zanettini C, Lynch AG, Wedge DC, Brewer DS, Woodcock DJ. Causes of evolutionary divergence in prostate cancer. *arXiv* [Preprint]. 2025 Mar 17; arXiv:2503.13189v1. PMID: 40166741.

Gheybi K, Soh PXY, Jiang J, Mbeki TMN, Louw M, Burns D, Mundra P, Kiriy D, Hasan MM, Jaratlersiri W, Lebelo MT, Campbell RA, Radzuma MB, Nenzhelele M, Obida M, Obida M, Ombuki WM, Oyaro MO, Patrick SM, Loda M, Wedge DC, Bristow RG, Brewer DS, Cooper CS, Reimand J, Cancel-Tassin G, Cussenot O, Hovens CM, Corcoran NM, Stricker PD, Schlomm T, Prins GS, Sørensen KD; Pan Prostate Cancer Group; HEROIC PCaPH Africa1K; Weischenfeldt J, Mutambirwa SBA, Ngugi PM, Thomas DM, Kote-Jarai Z, Eeles RA, Bornman MSR, Hayes VM. Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry. *Nat Commun*. 2025 Oct 2;16(1):8799. doi:10.1038/s41467-025-63865-6. PMID: 41038821.

Smith SF, Mills RD, Cooper CS, Brewer DS. Molecular and genetic biomarkers in prostate cancer active surveillance: recent developments and future perspectives. *Genes (Basel)*. 2026 Jan 6;17(1):71. doi:10.3390/genes17010071. PMID: 41595491.

Gihawi A, Wood HM, Clark J, O'Grady J, Eeles RA, Wedge DC, Jakobsdottir GM, Magiorkinis G, Schache AG, Masterson L, Lechner M, Fenton TR, Jones TM, Flanagan AM, De Noon S, Rubinsteyn A, Hurst R, Cooper CS, Brewer DS. The landscape of microbial associations in human cancer. *Sci Transl Med*. 2025 Sep 3;17(814):eads6166. doi:10.1126/scitranslmed.ads6166. PMID: 40901921.

Gruber A, Olsen AV, Girma EG, Hernando B, Torres Lázaro M, Macintyre G, Cheng K, Kiriy D, Reimand J, Pellegrina D, Gerhäuser C, Eeles R, Cooper C, Bristow R, Wedge D, Schlomm T, Fernandez-Sanroman A, Roldan-Romero JM, Lamy P, Sorensen K, Cancel-Tassin G, Cussenot O, Rausch T, Brors B, Uhrig S, Lutsik P, Yamaguchi T, Barton L, Jakobsdottir G, Sahli A, Simon R, Sauter G, Brewer D, He H, Bova S, Corcoran N, Hayes V, Brook M, Kote-Jarai Z, Hamid A, Hovens C, Jung CH, Pope B, Gnanapragasam V, Molania R, Papenfuss A, Imada EL, Khani F, Loda M, Marchionni L, Queiroz L, Robinson B, Zanettini C, Butler A, Leeman G, Xu Y, Favero F, Gihawi A. Integrated signatures define mutational processes in prostate cancer. *Nature. In press*.

Kiriy D, Favero F, Olsen AV, Gerhäuser C, Heilmann J, Lutsik P, Gruber A, Hernando B, Macintyre G, Cheng K, Reimand J, Pellegrina D, Cooper C, Schlomm T, Girma EG, Cancel-Tassin G, Cussenot O, Lamy P, Sorensen K, Imada EL, Khani F, Loda M, Marchionni L, Queiroz L, Robinson B, Zanettini C, Hovens C, Hamid A, Gnanapragasam V, Corcoran N, Brors B, Uhrig S, Jakobsdottir G, Rausch T, Yamaguchi T, Bristow R, Sahli A, Wedge D, Pope B, Jung CH, Brewer D, Gihawi A, He H, Bova GS, Hayes V, Brook M, Eeles R, Kote-Jarai Z, Molania R, Papenfuss A, Butler A, Leeman G, Xu Y, Pan

Prostate Cancer Group (PPCG), Jespersen J, Rodriguez-Gonzalez F, Locallo A. Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer. *Nat Commun. In press*.

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2025

Financial Review

The Trust incurred an overall surplus for the year of £31,963 (2024: £332,459). Included within the income and expenditure of the Trust for the year is a surplus on fundraising events of £118,662 (2024: £184,412) and dividends received of £52,752 (2024: £46,708). In addition, the unrealised loss on investments for the year to 30 June 2025 was £93,404 (2024: gain £112,344).

The Trustees are satisfied that the charity's funds are available and adequate to fulfil its obligations in relation to their commitments.

The Declaration of Trust, signed on the 29th June 1993, states that "any money available for investment may be so invested in the names of the Trustees or their nominees in any way whatsoever, whether or not producing income, as the Trustees shall in their absolute discretion think fit, as if they were absolutely entitled to the Trust Fund beneficially."

It is the policy of the charity to hold reserves in its General Fund that have not yet been committed or designated for any particular purpose. The Trustees have set aside these reserves in order to protect the future operations of the charity from the effects of any unforeseen variations in its income streams as part of a policy of good financial management practice.

Plans for the Future

The Trustees continue to work towards the aims of the deed of declaration of Trust to find a cure for urological cancers, particularly prostate cancer, through scientific and clinical research at the Institute of Cancer Research and The Norwich Medical Research Park at UEA. To establish a clinical test to detect prostate cancer cells remains at the forefront of the Trusts current plans.

To establish a clinical test to detect aggressive prostate cancer cells remains at the forefront of the Trust's plans.

The Trust has approved two grants at the ICR involving AI powered technology - The Nick & Valda Embiricos Award. The first project under the award will focus on accelerating MRI with trustworthy AI that could reduce prostate screening times to just five minutes. The second project utilises advanced AI to analyse routine biopsy samples helping clinicians predict aggressive prostate disease and which prostate cancer patients are most likely to have a recurrence.

The funding for the work of the Trust will continue to be raised from a full fundraising calendar run by the Executive Officer of the Charity, donations and legacies and the interest from the investment funds if required.

Approval

This report was approved by the Trustees and signed on its behalf by:

DocuSigned by:

D17B32C730044CE...
Michael Cattermole
Trustee

DocuSigned by:

079866F1D2FDACA...
Luke Ponsonby
Trustee

Date: 02 April 2026

Bob Champion Cancer Trust

Statement of Trustees' responsibilities For the year ended 30 June 2025

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust Deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on its behalf by:

DocuSigned by:

D17B32C730044CE...

Michael Cattermole
Trustee
Date: 02 April 2026

DocuSigned by:

079866F1D2FD4CA...

Luke Ponsonby
Trustee

Bob Champion Cancer Trust

Independent Examiner's Report For the year ended 30 June 2025

Independent Examiner's Report to the Trustees of Bob Champion Cancer Trust ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 30 June 2025.

Responsibilities and Basis of Report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants England and Wales, which is one of the listed bodies.

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed: 
1102ED52BDD84BD...

Dated: 02 April 2026

Tracey Moore BFP ACA

UHY Hacker Young

Chartered Accountants

Bob Champion Cancer Trust

Statement of financial activities
For the year ended 30 June 2025

	Note	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Income from:				
Donations and legacies	4	253,529	253,529	209,883
Other trading activities - Fundraising	5	249,189	249,189	359,344
Investments	6	52,752	52,752	46,708
Total income		555,470	555,470	615,935
Expenditure on:				
Raising funds	7	130,527	130,527	174,932
Charitable activities		299,576	299,576	220,888
Total expenditure		430,103	430,103	395,820
Net income before net (losses)/gains on investments		125,367	125,367	220,115
Net (losses)/gains on investments		(93,404)	(93,404)	112,344
Net movement in funds		31,963	31,963	332,459
Reconciliation of funds:				
Total funds brought forward		1,861,310	1,861,310	1,528,851
Net movement in funds		31,963	31,963	332,459
Total funds carried forward	18	1,893,273	1,893,273	1,861,310

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 14 to 28 form part of these financial statements.

Bob Champion Cancer Trust

Balance sheet
As at 30 June 2025

	Note	2025 £	2024 £
Fixed assets			
Tangible assets	13	1,183	1,571
Investments	14	1,850,136	1,693,539
		<u>1,851,319</u>	<u>1,695,110</u>
Current assets			
Debtors	15	1,216	1,861
Cash at bank and in hand		120,777	192,340
		<u>121,993</u>	<u>194,201</u>
Current liabilities			
Creditors: amounts falling due within one year	16	(80,039)	(28,001)
Net current assets		<u>41,954</u>	<u>166,200</u>
Total net assets		<u><u>1,893,273</u></u>	<u><u>1,861,310</u></u>
Charity funds			
Unrestricted funds	18	1,893,273	1,861,310
Total funds		<u><u>1,893,273</u></u>	<u><u>1,861,310</u></u>

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

DocuSigned by:

 D17B32C730044CE...

Michael Cattermole
Trustee

Date: 02 April 2026

DocuSigned by:

 079866F1D2FD4CA...

Luke Ponsonby
Trustee

The notes on pages 14 to 28 form part of these financial statements.

Bob Champion Cancer Trust

Statement of cash flows
For the year ended 30 June 2025

	Note	2025 £	2024 £
Cash flows from operating activities			
Net cash used in operating activities	20	125,685	131,029
Cash flows from investing activities			
Dividends, interests and rents from investments		52,752	46,708
Purchase of property, plant and equipment		-	(935)
Purchase of investments		(250,000)	(75,000)
Net cash (used in)/provided by investing activities		(197,248)	(29,227)
Change in cash and cash equivalents in the year			
Cash and cash equivalents at the beginning of the year		192,340	90,538
Cash and cash equivalents at the end of the year	21	120,777	192,340

The notes on pages 14 to 28 form part of these financial statements

Bob Champion Cancer Trust

Notes to the financial statements For the year ended 30 June 2025

1. General information

Bob Champion Cancer Trust is a registered charity in England and Wales registered under the charity number 1024664. The registered office is 7 Square Rigger Row, Plantation Wharf, London, SW11 3TZ.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Bob Champion Cancer Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The charity has taken advantage of the exemption available to smaller charities from preparing a cash flow statement.

2.2 Basis of non-consolidation

In the opinion of the Trustees, the charity and its subsidiary undertaking comprise a small group. The subsidiary has been excluded as its inclusion would not be material from the point of view of providing a true and fair view.

2.3 Going concern

The Trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern for a period of at least twelve months after the date of signature of these accounts. The accounts have therefore been prepared on the going concern basis.

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2025**

2. Accounting policies (continued)**2.4 Income**

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time is not recognised and refer to the Trustees' report for more information about their contribution.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

2.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include management carried out by the Executive Officer. The Trust office is based on an office share which is donated to the Trust by the building owner.. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2025**

2. Accounting policies (continued)**2.6 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.7 Tangible fixed assets and depreciation

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Fixtures and fittings	-	20% reducing balance
Computer equipment	-	25% reducing balance

2.8 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of financial activities.

Investments in subsidiaries are valued at cost less provision for impairment.

2.9 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.10 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2025**

2. Accounting policies (continued)**2.11 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

2.12 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.13 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

2.14 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Investment income, gains and losses are allocated to the appropriate fund.

3. Critical accounting estimates and areas of judgment

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Trustees have not applied any significant estimates or judgments in the preparation of these financial statements.

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2025

4. Income from donations and legacies

	Unrestricted funds 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Donations	6,640	6,640	10,148
Legacies	246,889	246,889	199,735
Total 2025	<u>253,529</u>	<u>253,529</u>	<u>209,883</u>

In both the current and prior year all income from donations and legacies was in relation to unrestricted funds.

5. Income from other trading activities - fundraising
Income from fundraising events

	Unrestricted funds 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
General Fundraising	32,227	32,227	35,528
Christmas Season	22,480	22,480	30,046
Carols and Champagne	-	-	60,918
Shetland Pony Grand National	40,889	40,889	12,000
Plumpton Raceday	122,279	122,279	122,749
Wincanton Raceday	-	-	98,103
South Downs Way Ride	10,794	10,794	-
Golf Day	432	432	-
Sandringham Holts	20,088	20,088	-
Total 2025	<u>249,189</u>	<u>249,189</u>	<u>359,344</u>

In both the current and prior year all income from fundraising was in relation to unrestricted funds.

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2025

6. Investment income

	Unrestricted funds 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Listed securities	50,231	50,231	43,799
Bank deposits	2,521	2,521	2,909
Total 2025	<u>52,752</u>	<u>52,752</u>	<u>46,708</u>

In both the current and prior year all income from investments was in relation to unrestricted funds.

7. Expenditure on raising funds
Publicity and fundraising expenses

	Unrestricted funds 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
General Fundraising costs	18,403	18,403	14,340
Christmas Season	15,696	15,696	13,780
Carols and Champagne	-	-	14,753
Shetland Pony Grand National	1,634	1,634	952
Plumpton Raceday	50,458	50,458	46,104
Wincanton Raceday	-	-	41,341
Publicity and direct administrative costs	44,336	44,336	43,662
	<u>130,527</u>	<u>130,527</u>	<u>174,932</u>
<i>Total 2024</i>	<u>174,932</u>	<u>174,932</u>	

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2025

8. Research Grants

	Grants to Institutions 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Professor Rosalind Eeles grant - Institute of Cancer Research (ICR)	144,734	144,734	84,998
Professor Colin Cooper grant - UEA	8,985	8,985	13,588
Clinician Annie Gao	59,765	59,765	31,543
Total 2025	<u>213,484</u>	<u>213,484</u>	<u>130,129</u>

Professor Ros Eeles, Prostate Cancer Sequencing Germline DNA Project at the ICR, to predict who will develop aggressive or lethal prostate cancer commenced in August 2019 at cost of £282,509 over the three year grant period. Due to Covid-19 delays the grant ended, and was then extended for a further three years in October 2023 at the cost of £349,294.

Professor Colin Cooper, The Role of Bacterial Infection in the Development of Human Prostate Cancer grant for Rachel Hurst was awarded initially in January 2020 for two years at a cost of £80,000. The BCCT continued to fund this project with Rachel Hurst to 31 December 2024 with BCCT paying 75% of the total grant, approximately £50,000 per annum. The Trust then extended the grant, including the appointment of a Phd student, to gain further evidence that bacteria are causally involved in the development of aggressive prostate cancer, as a first step towards launching the PathoProsect Clinical Trial. To assess whether using bacteria can improve the prediction of aggressive disease when using the PUR test. Extended in February 2025 for three years at a combined cost of £66,050 per year.

Dan Brewer within Professor Colin Cooper's team on the DESNT project this grant covers the project for one year at £30,000, with a deadline of completion of December 2023.

In July 2021 a three year grant was awarded to Annie Gao within the Bob Champion Unit at the ICR/RMH. The agreed funding for £42,000 per year (including standard on-costs) commenced 1st September. This grant was extended for a further three years in July 2024 including for a Trials Assistant, Lily Gilder, at a combined cost of £56,44 per year.

The Trustees are satisfied that the charity will have sufficient resources to fulfil future research grant commitments. The charity has a strong balance sheet position, which includes listed investments of £1,693,539 that can be turned into cash as required.

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2025**

9. Charitable expenditure

	Grant funding of activities 2025 £	Support costs 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Grants to institutions (note 8)	213,484	-	213,484	130,129
Staff costs	59,668	-	59,668	63,360
Depreciation	388	-	388	483
Premises costs	4,657	-	4,657	5,755
Travel costs	695	-	695	1,041
Computer and IT costs	2,990	-	2,990	3,049
General office costs	8,038	-	8,038	7,650
Governance costs	9,656	-	9,656	9,421
	<u>299,576</u>	<u>-</u>	<u>299,576</u>	<u>220,888</u>
<i>Total 2024</i>	<u>130,129</u>	<u>90,759</u>	<u>220,888</u>	

Governance costs comprise Trustees' indemnity insurance and independent examiner's fees.

10. Independent examiner's remuneration

	2025 £	<i>2024 £</i>
Fees payable to the Charity's independent examiner for the independent examination of the Charity's annual accounts	<u>5,250</u>	<u>5,100</u>

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2025

11. Staff costs

	2025	<i>2024</i>
	£	£
Wages and salaries	56,500	<i>60,000</i>
Social security costs	1,473	<i>1,618</i>
Contribution to defined contribution pension schemes	1,695	<i>1,742</i>
	<u>59,668</u>	<u><i>63,360</i></u>

The average number of persons employed by the Charity during the year was as follows:

	2025	<i>2024</i>
	No.	No.
Employees	<u>1</u>	<u><i>1</i></u>

No employee received remuneration amounting to more than £60,000 in either year.

Key management personnel comprise of the Trustees and the Executive Director. Total employment benefits (including social security contributions and employers' pension contributions) of key management personnel during the year were £59,668 (*2024: £63,360*).

12. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (*2024 - £NIL*).

During the year, no donations were given by Trustees (*2024: £1,698*).

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2025

13. Tangible fixed assets

	Fixtures and fittings £	Office equipment £	Total £
Cost			
At 1 July 2024	118	7,599	7,717
At 30 June 2025	<u>118</u>	<u>7,599</u>	<u>7,717</u>
Depreciation			
At 1 July 2024	24	6,122	6,146
Charge for the year	19	369	388
At 30 June 2025	<u>43</u>	<u>6,491</u>	<u>6,534</u>
Net book value			
At 30 June 2025	<u>75</u>	<u>1,108</u>	<u>1,183</u>
<i>At 30 June 2024</i>	<u>94</u>	<u>1,477</u>	<u>1,571</u>

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2025**

14. Fixed asset investments

	Investments in subsidiary companies £	Listed investments £	Total £
Cost or valuation			
At 1 July 2024	2	1,693,538	1,693,540
Additions	-	250,000	250,000
Revaluations	-	(93,404)	(93,404)
At 30 June 2025	2	1,850,134	1,850,136

At 30 June 2025, CCLA Fund Managers Limited, an investment management company external to the charity, valued the investments held by the charity at £1,850,134 (2024: £1,693,538). This valuation was made on the basis of the value of the units on the open market in which they are traded. The gain/(loss) is included in the statement of financial activities.

Subsidiary undertakings

The following was a subsidiary undertaking of the Charity:

Name	Holding	Included in consolidation
Aldaniti Trading Company Limited	100%	No

The financial results of the subsidiary for the year were:

Name	Net assets £
Aldaniti Trading Company Limited	2

Aldaniti Trading Company Limited, a company incorporated in England and Wales, ceased trading on 30 June 2004 and has not traded since. On this date its trade and assets were transferred to the charity.

15. Debtors

	2025 £	2024 £
Prepayments	1,216	1,861

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2025

16. Creditors: Amounts falling due within one year

	2025	<i>2024</i>
	£	£
Trade creditors	-	1,649
Amounts owed to group undertakings	2	2
Other taxation and social security	468	662
Other creditors	436	3,327
Accruals and deferred income	79,133	22,361
	<u>80,039</u>	<u>28,001</u>
	2025	<i>2024</i>
	£	£
Deferred income at 1 July 2024	8,967	12,975
Events income deferred during the year	20,512	8,967
Amounts released from previous periods	(8,967)	(12,975)
	<u>20,512</u>	<u>8,967</u>

17. Financial instruments

	2025	<i>2024</i>
	£	£
Financial assets		
Financial assets measured at fair value through income and expenditure	<u>1,850,134</u>	<u>1,693,538</u>

Financial assets measured at fair value through income and expenditure comprise fixed asset investments. Fair value has been determined on the basis of the value of the investment units on the open market in which they are traded.

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2025**

18. Statement of funds

Statement of funds - current year

	Balance at 1 July 2024	Income	Expenditure	Gains/ (Losses)	Balance at 30 June 2025
	£	£	£	£	£
Unrestricted funds					
Reserves	1,861,310	555,470	(430,103)	(93,404)	1,893,273

Statement of funds - prior year

	<i>Balance at 1 July 2022</i>	<i>Income</i>	<i>Expenditure</i>	<i>Gains/ (Losses)</i>	<i>Balance at 30 June 2024</i>
	£	£	£	£	£
Unrestricted funds					
Reserves	1,528,851	615,935	(395,820)	112,344	1,861,310

19. Analysis of net assets between funds

	Unrestricted funds 2025	Total funds 2025	<i>Total funds 2024</i>
	£	£	£
Tangible fixed assets	1,183	1,183	1,571
Fixed asset investments heading	1,850,136	1,850,136	1,693,539
Current assets	121,993	121,993	194,201
Creditors due within one year	(80,039)	(80,039)	(28,001)
	<u>1,893,273</u>	<u>1,893,273</u>	<u>1,861,310</u>

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2025

20. Reconciliation of net movement in funds to net cash flow from operating activities

	2025	2024
	£	£
Net income for the year (as per Statement of Financial Activities)	31,963	332,459
	<hr/>	<hr/>
Adjustments for:		
Depreciation charges	388	483
Gains/(losses) on investments	93,403	(112,344)
Dividends, interests and rents from investments	(52,752)	(46,708)
Decrease in debtors	645	2,421
Increase/(decrease) in creditors	52,038	(45,282)
	<hr/>	<hr/>
Net cash provided by operating activities	125,685	131,029
	<hr/> <hr/>	<hr/> <hr/>

21. Analysis of cash and cash equivalents

	2025	2024
	£	£
Cash in hand	120,777	192,340
	<hr/>	<hr/>
Total cash and cash equivalents	120,777	192,340
	<hr/> <hr/>	<hr/> <hr/>

22. Analysis of changes in net debt

	At 1 July	Cash flows	At 30 June
	2024	£	2025
	£	£	£
Cash at bank and in hand	192,340	(71,563)	120,777
	<hr/>	<hr/>	<hr/>
	192,340	(71,563)	120,777
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

23. Pension commitments

The group operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the group in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £1,695 (2024: £1,680). Contributions totaling £338 (2024: £327) were payable to the fund at the balance sheet date and are included in creditors.

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2025**

24. Related party transactions

During the year, the charity paid £23,324 (2024: £29,387) to the president of the charity, Mr. Bob Champion, in relation to fees and expenses incurred in fulfilling his duties. The amount outstanding at the year end was £7,095 (2024: £7,274). Bob Champion's retainer has been approved by the Charity Commission.